Stock Notes

Biocon

Every Finvezto stock note on Biocon, dated and newest first. Coverage spans pharma, pharmaceuticals, pharmaceuticals / biosimilars.

5 notes and counting
25 Sep 2026
Biocon Malaysia won UK MHRA approval for its new drug product fill finish unit for insulins.
The line already held EMA clearance from July, so both large European markets are now open to it. Commercial supplies to Europe are expected from the second quarter of FY2026-27.
21 Sep 2026
Biocon's Pertuzumab biosimilar Pebrilzo won a positive CHMP opinion, the first monoclonal antibody biosimilar under the EMA's tailored pathway.
The file rested on analytical characterisation and comparative pharmacokinetics instead of a full efficacy trial. The European Commission decides marketing authorisation next.
08 Sep 2026
Biocon won 100 percent allocation under Brazil's 10 year Productive Development Partnership for Pertuzumab, alongside Bahiafarma and Bionovis.
The consortium gets exclusive access to Brazil's public health system, about 70 percent of the country's Pertuzumab demand. Biocon earns milestones and a revenue share, and localises production in phases.
25 Aug 2026
Japan's health ministry approved Biocon Biologics' pegfilgrastim biosimilar, a version of the cancer supportive-care drug Neulasta.
Sandoz holds exclusive selling rights in Japan, so Biocon earns manufacturing economics rather than the shelf price.
03 Aug 2026
Biocon launched Yesafili commercially in the United States, an interchangeable biosimilar to Regeneron's Eylea 2 mg.
The launch follows a settlement with Regeneron that fixed the US entry window, on an approval the FDA granted in 2024. Interchangeable status is the commercial lever: a pharmacist can substitute it for Eylea without the prescriber intervening, which is how a biosimilar takes share quickly rather than converting physicians one patient at a time.
Finvezto Membership

Get the research behind the notes

Stock notes are the free daily layer. The membership carries the full Flexi-Wealth system: an ETF core portfolio with monthly rebalancing signals, fifteen quality-momentum stocks with exact weightages every month, options income and hedging recommendations, and the institutional data toolkit. One flat membership covers everything.

Become a Member Read free sample research →

Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630. Stock notes are market commentary for general information and education. They are not investment advice, not a recommendation to buy or sell, and do not account for any individual's financial situation. Investment in securities is subject to market risks. Please read all related documents carefully before investing. Past performance is not a guarantee of future results.